Surterra partners with Intrexon in $100 million licensing cannabinoid deal

Be at the forefront of cannabis and psychedelics science and innovation. Register today & Save $200 on tickets to The Emerald Conference by MJBiz Science, April 1-3 in San Diego.

Surterra Wellness, an Atlanta-based cannabis company with operations in Florida and Texas, announced it will partner with Hungary’s Intrexon Corp. in a $100 million licensing deal aimed at biosynthetic cannabinoid production.

Surterra would use Intrexon’s proprietary yeast fermentation platform to boost its cannabinoid production.

Surterra is a privately held company; Intrexon trades on the Nasdaq under the ticker symbol XON.

This is the second deal between the two companies this year: They earlier announced a collaboration on cannabis plant propagation.

More details on the cannabinoid agreement can be found here.

Get access to more in-depth market analysis, premium features on cannabis investing trends and monthly executive webcasts with an Investor Intelligence subscription.